Physician profile
Robin Park
NPI 1407871213
$5,790.08
in general payments reported to CMS, 2019-2025
29 companies · $1,076 in 2025
The $1,076 reported for 2025 was more than what 82% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,202 · 2020: $462 · 2021: $160 · 2022: $878 · 2023: $966 · 2024: $1,046 · 2025: $1,076.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,012 · Education: $75.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,012.32 |
| Education | $75.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $1,783.49 | 2021-2025 | Azstarys |
| Neos Therapeutics, Lp | $453.75 | 2019-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Neurocrine Biosciences, INC. | $394.11 | 2022-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $267.08 | 2019-2025 | Rexulti, Abilify Maintena |
| Tris Pharma INC | $265.47 | 2019-2025 | Dyanavel Xr, Onyda Xr |
| Supernus Pharmaceuticals, INC. | $251.51 | 2021-2025 | Qelbree |
| Ironshore Pharmaceuticals INC. | $247.89 | 2019-2022 | |
| Allergan, INC. | $223.77 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $221.10 | 2019-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $216.25 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Janssen Pharmaceuticals, INC | $194.32 | 2019-2025 | Spravato |
| Rhodes Pharmaceuticals L.P. | $180.66 | 2019 | |
| Vanda Pharmaceuticals INC. | $170.05 | 2019-2024 | Fanapt |
| Lundbeck LLC | $114.30 | 2019-2024 | Rexulti |
| Avanir Pharmaceuticals, INC. | $113.37 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $98.60 | 2022-2024 | Caplyta |
| Abbvie INC. | $94.11 | 2022-2025 | |
| Alkermes, INC. | $77.82 | 2022-2023 | Aristada, Lybalvi |
| Shire North American Group INC | $74.29 | 2019 | |
| Adlon Therapeutics L.P. | $66.63 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $61.11 | 2019 | |
| Noven Therapeutics, LLC | $55.53 | 2023-2024 | Xelstrym |
| Idorsia Pharmaceuticals US INC | $52.08 | 2023 | Quviviq |
| Arbor Pharmaceuticals, INC. | $34.51 | 2019-2020 | |
| Novo Nordisk INC | $21.63 | 2023 | Wegovy |
| Bausch Health US, LLC | $15.60 | 2022 | |
| Alfasigma USA, INC. | $15.00 | 2020 | |
| Collegium Pharmaceutical, INC. | $14.79 | 2025 | Jornay Pm |
| Eisai INC. | $11.26 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.